SEC Form 4 · accession 0001123292-16-002778
Zynerba Pharmaceuticals, Inc. · ZYNE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James E Fickenscher
Officer — Chief Financial Officer
Period of report
Sep 13, 2016
Accepted (ET)
Sep 22, 2016 · 3:58 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001621443
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.23 | Sep 13, 2016 | A | 150,000 | A | — | Sep 13, 2026 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The stock option vests 25% on the first anniversary of the date of the grant, with the remainder vesting in 12 equal quarterly installments thereafter, subject to continued employment with the Company. The stock option is an inducement grant under NASDAQ listing rule 5635(c)(4).